BR0214357A - Formulações farmacêuticas compreendendo derivados de indolinona - Google Patents

Formulações farmacêuticas compreendendo derivados de indolinona

Info

Publication number
BR0214357A
BR0214357A BR0214357-7A BR0214357A BR0214357A BR 0214357 A BR0214357 A BR 0214357A BR 0214357 A BR0214357 A BR 0214357A BR 0214357 A BR0214357 A BR 0214357A
Authority
BR
Brazil
Prior art keywords
formulations
indolinone derivatives
pharmaceutical formulations
activity
methods
Prior art date
Application number
BR0214357-7A
Other languages
English (en)
Inventor
Ping Gao
Anand Sistla
Narmada Shenoy
Original Assignee
Sugen Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Upjohn Co filed Critical Sugen Inc
Publication of BR0214357A publication Critical patent/BR0214357A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"FORMULAçõES FARMACêUTICAS COMPREENDENDO DERIVADOS DE INDOLINONA". A presente invenção refere-se a formulações compreendendo derivados de 3-(pirrol-2-ilmetilideno)-2-indolinona que modulam a atividade de proteína cinases (PKs). Métodos de tratamento de doenças relacionadas com atividade de PK anormal que utilizam as formulações compreendendo estes compostos e métodos de fabricação destas formulações são também revelados.
BR0214357-7A 2001-11-21 2002-11-21 Formulações farmacêuticas compreendendo derivados de indolinona BR0214357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33180001P 2001-11-21 2001-11-21
PCT/US2002/037233 WO2003045307A2 (en) 2001-11-21 2002-11-21 Pharmaceutical formulations comprising indolinone derivatives

Publications (1)

Publication Number Publication Date
BR0214357A true BR0214357A (pt) 2004-09-14

Family

ID=23295427

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214357-7A BR0214357A (pt) 2001-11-21 2002-11-21 Formulações farmacêuticas compreendendo derivados de indolinona

Country Status (8)

Country Link
US (1) US7109185B2 (pt)
EP (1) EP1453502A4 (pt)
JP (1) JP2005514368A (pt)
AU (1) AU2002346457A1 (pt)
BR (1) BR0214357A (pt)
CA (1) CA2466807A1 (pt)
MX (1) MXPA04004804A (pt)
WO (1) WO2003045307A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
US20070128137A1 (en) * 2005-12-02 2007-06-07 Naohisa Yoshimi Water in oil emulsion compositions containing siloxane elastomers
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
EP2076492A4 (en) * 2006-10-06 2010-12-22 Merck Sharp & Dohme NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
JP5591720B2 (ja) * 2009-01-29 2014-09-17 株式会社林原 抗神経変性疾患剤
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
CN104829596B (zh) 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4940469A1 (es) * 1997-03-05 2000-07-24 Sugen Inc Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
US6313158B1 (en) * 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
EP1259234B9 (en) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer

Also Published As

Publication number Publication date
AU2002346457A1 (en) 2003-06-10
CA2466807A1 (en) 2003-06-05
JP2005514368A (ja) 2005-05-19
US7109185B2 (en) 2006-09-19
WO2003045307A3 (en) 2004-01-15
EP1453502A4 (en) 2007-01-10
EP1453502A2 (en) 2004-09-08
WO2003045307A2 (en) 2003-06-05
MXPA04004804A (es) 2005-02-17
US20030176399A1 (en) 2003-09-18
AU2002346457A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2001090103A3 (en) 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
WO2001094312A3 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0410711A (pt) novos compostos
NO20045589L (no) Nye forbindelser
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
ME00513B (me) Azabicikloalkani kao modulatori ccr5
BR0307631A (pt) Piridinonas substituìdas como moduladores de p38 map-quinase
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
BR0014073A (pt) Pirazolopirimidinas como agentes terapêuticos
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
YU40701A (sh) Piperidini kao modulatori ccr5
ATE408601T1 (de) Fredericamycin-derivate
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BR0214357A (pt) Formulações farmacêuticas compreendendo derivados de indolinona
NO20032758D0 (no) Krystallinske former av Atorvastatin
BRPI0411017A (pt) indóis 3-substituìdos e derivados dos mesmos como agentes terapêuticos
AR032293A1 (es) Estuche farmaceutico
BR0214672A (pt) Inibidores de fosfolipase citosólica a2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired